NasdaqCM:AXGNMedical Equipment
Why Axogen (AXGN) Is Up 6.9% After Raising 2026 Revenue Guidance Despite First-Half Loss
In the second quarter of 2026, Axogen reported sales of US$69.73 million, up from US$56.66 million a year earlier, but moved from a net income of US$0.579 million to a net loss of US$1.52 million, with both basic and diluted loss per share from continuing operations at US$0.03.
Despite higher losses for both the quarter and first half of 2026, Axogen raised its full-year 2026 revenue guidance to at least US$279 million, highlighting management’s increased confidence in the company’s top-line...